Epix touts data on pulmonary hypertension drug
Shares of Epix Pharmaceuticals were buoyed this morning by positive data from a mid-stage study of a drug designed to reduce high blood pressure in the pulmonary artery. The trial of PRX-08066 involved 71 patients with pulmonary hypertension associated with COPD. Lexington, MA-based Epix also reported that its losses ballooned in the second quarter due to swelling R&D costs.
- see the release for more
Related Articles:
Epix shares soar on $1.2B pact with GSK. Report
Epix anxiety drug fails in late-stage trial. Report
Epix to buy Predix in $90M merger. Report
More stories about pharmaceuticals GlaxoSmithKline Drug Trials blood pressure COPD EPIX Pharmaceuticals


SHARE
WITH: